Zosano Pharma Corporation (ZSAN)
US98979H3012 - Common Stock
ZSAN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. ZSAN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ZSAN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ZSAN has reported negative net income.
In the past 5 years ZSAN always reported negative net income.
ZSAN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -208.66% | ||
| ROE | 41.36% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -4681.82% | ||
| PM (TTM) | -8362.12% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ZSAN has less shares outstanding
The debt/assets ratio for ZSAN has been reduced compared to a year ago.
2.2 Solvency
ZSAN has an Altman-Z score of -27.38. This is a bad value and indicates that ZSAN is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for ZSAN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -27.38 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ZSAN has a Current Ratio of 1.61. This is a normal value and indicates that ZSAN is financially healthy and should not expect problems in meeting its short term obligations.
ZSAN has a Quick Ratio of 1.61. This is a normal value and indicates that ZSAN is financially healthy and should not expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.61 |
3. Growth
3.1 Past
The earnings per share for ZSAN have decreased strongly by -1951.22% in the last year.
The Revenue has grown by 37.50% in the past year. This is a very strong growth!
The Revenue has been decreasing by -6.63% on average over the past years.
EPS 1Y (TTM)-1951.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2100%
Revenue 1Y (TTM)37.5%
Revenue growth 3YN/A
Revenue growth 5Y-6.63%
Sales Q2Q%-50%
3.2 Future
ZSAN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.47% yearly.
ZSAN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.92% yearly.
EPS Next Y98.64%
EPS Next 2Y40.94%
EPS Next 3Y25.57%
EPS Next 5Y18.47%
Revenue Next Year-90.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ZSAN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZSAN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.31 |
4.3 Compensation for Growth
A more expensive valuation may be justified as ZSAN's earnings are expected to grow with 25.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.94%
EPS Next 3Y25.57%
5. Dividend
5.1 Amount
No dividends for ZSAN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Zosano Pharma Corporation
NASDAQ:ZSAN (6/10/2022, 8:00:56 PM)
After market: 0.5459 -0.01 (-2.1%)0.5576
+0.04 (+7.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners2.49%
Inst Owner Change0%
Ins Owners323.29%
Ins Owner Change0%
Market Cap2.73M
Analysts45.71
Price Target21.42 (3741.46%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.14 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | 0.31 |
EPS(TTM)-8.41
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.13
BVpS2.87
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -208.66% | ||
| ROE | 41.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -4681.82% | ||
| PM (TTM) | -8362.12% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y1%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.61 | ||
| Altman-Z | -27.38 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1951.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2100%
EPS Next Y98.64%
EPS Next 2Y40.94%
EPS Next 3Y25.57%
EPS Next 5Y18.47%
Revenue 1Y (TTM)37.5%
Revenue growth 3YN/A
Revenue growth 5Y-6.63%
Sales Q2Q%-50%
Revenue Next Year-90.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A